BACKGROUND: There are no published prospective trials of chemotherapy for advanced bronchioloalveolar carcinoma (BAC), a subtype of non-small-cell lung cancer for which there is no current standard therapy. This phase II study assesses the efficacy and toxicity of 96-h paclitaxel in chemotherapy-naive patients with advanced BAC. PATIENTS AND METHODS: Patients with histologically confirmed stage IIIB (with pleural effusion) or stage IV BAC were eligible. Treatment consisted of paclitaxel 35 mg/m2/24 h continuously infused over 96 h (days 1-4) every 21 days for up to six courses. RESULTS: A total of 58 eligible patients were enrolled. The objective response rate was 14% (all partial responses, 9% confirmed); 40% of patients demonstrated stable disease. The median progression-free and overall survivals were 5 and 12 months, respectively. Grade 3 or greater toxicities included neutropenia/granulocytopenia (43%), febrile neutropenia (12%), infection (22%), and stomatitis/pharyngitis (10%); there were five treatment-related deaths. CONCLUSIONS: S9714 represents the first prospective multi-institutional cooperative group trial focusing on treatment outcomes in BAC. Studies targeting this population are feasible, and while first-line paclitaxel administered as a prolonged infusion is active in this setting, toxicities limits the utility of this regimen. S9714 serves as a historical control for BAC patients against which future therapeutic approaches can be compared.
BACKGROUND: There are no published prospective trials of chemotherapy for advanced bronchioloalveolar carcinoma (BAC), a subtype of non-small-cell lung cancer for which there is no current standard therapy. This phase II study assesses the efficacy and toxicity of 96-h paclitaxel in chemotherapy-naive patients with advanced BAC. PATIENTS AND METHODS: Patients with histologically confirmed stage IIIB (with pleural effusion) or stage IV BAC were eligible. Treatment consisted of paclitaxel 35 mg/m2/24 h continuously infused over 96 h (days 1-4) every 21 days for up to six courses. RESULTS: A total of 58 eligible patients were enrolled. The objective response rate was 14% (all partial responses, 9% confirmed); 40% of patients demonstrated stable disease. The median progression-free and overall survivals were 5 and 12 months, respectively. Grade 3 or greater toxicities included neutropenia/granulocytopenia (43%), febrile neutropenia (12%), infection (22%), and stomatitis/pharyngitis (10%); there were five treatment-related deaths. CONCLUSIONS: S9714 represents the first prospective multi-institutional cooperative group trial focusing on treatment outcomes in BAC. Studies targeting this population are feasible, and while first-line paclitaxel administered as a prolonged infusion is active in this setting, toxicities limits the utility of this regimen. S9714 serves as a historical control for BAC patients against which future therapeutic approaches can be compared.
Authors: Suresh S Ramalingam; Ju-Whei Lee; Chandra P Belani; Seena C Aisner; Jill Kolesar; Craig Howe; Mario R Velasco; Joan H Schiller Journal: J Clin Oncol Date: 2011-03-21 Impact factor: 44.544
Authors: Derick H M Lau; James Moon; Angela M Davies; Rachel E Sanborn; Fred R Hirsch; Wilbur A Franklin; Janet C Ruzich; Mary W Redman; David R Gandara Journal: Clin Lung Cancer Date: 2013-02-14 Impact factor: 4.785
Authors: Suresh S Ramalingam; Angela M Davies; Jeffrey Longmate; Martin J Edelman; Primo N Lara; Everett E Vokes; Miguel Villalona-Calero; Barbara Gitlitz; Karen Reckamp; Ravi Salgia; John J Wright; Chandra P Belani; David R Gandara Journal: J Thorac Oncol Date: 2011-10 Impact factor: 15.609
Authors: Junji Tsurutani; Seth M Steinberg; Marc Ballas; Matthew Robertson; Jaclyn LoPiccolo; Hiroshi Soda; Shigeru Kohno; Valgardur Egilsson; Phillip A Dennis Journal: Lung Cancer Date: 2006-11-13 Impact factor: 5.705
Authors: Dirk Van Raemdonck; Robin Vos; Jonas Yserbyt; Herbert Decaluwe; Paul De Leyn; Geert M Verleden Journal: J Thorac Dis Date: 2016-11 Impact factor: 2.895